StocksR › RMBS

Rambus Inc. (RMBS) — Earnings Call X-Ray

Our AI read all 38 of RMBS's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2025 · sign up to see
Previous Call Grade
A
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
38
2016–2025
Avg Candor
6.9/9
evasion 2.5/9
High CandorSkeptic ReassuredClean CallVolume Step-UpEarly Product, Fast GrowthDemand Accelerating

Call-by-call analysis

🔒 Q1 2025 earnings call 2025-04-28 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2025 call grade is ready
The full 37-point AI read of RMBS's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

A Q4 2024 earnings call 2025-02-03 move ±14.8%

Management held guidance steady against accelerating demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: acceleratingMargins: stablePricing: stableHeadcount: flatCapex: flat 6 analysts · 15 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 1/9
Confidence 8/9
Uncertainty 2/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q3 2024 earnings call 2024-10-29 move ±12.1%

Management raised guidance against accelerating demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: stablePricing: stableHeadcount: flatCapex: decreasing 5 analysts · 11 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

A Q2 2024 earnings call 2024-07-29 move ±22.1%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: flatCapex: decreasing 4 analysts · 9 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO

B+ Q1 2024 earnings call 2024-04-29 move ±16.5%

Management held guidance steady against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: acceleratingMargins: contractingBacklog: stablePricing: under pressureHeadcount: flatCapex: increasing 4 analysts · 13 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 5/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B Q4 2023 earnings call 2024-02-05 move ±25.2%

Management held guidance steady against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: stablePricing: stableHeadcount: flatCapex: increasing 4 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
Candor 8/9
Specificity 8/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 4/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B Q3 2023 earnings call 2023-10-30 move ±18.4%

Management held guidance steady against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: stablePricing: under pressureHeadcount: cuttingCapex: decreasing 5 analysts · 9 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B Q2 2023 earnings call 2023-07-31 move ±19.5%

Management held guidance steady against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: stableBacklog: shrinkingPricing: under pressureHeadcount: flatCapex: decreasing 4 analysts · 8 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 7/9
Uncertainty 5/9
Promotion 4/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2023 2023-05-01 C+ maintainedmixedstable 7/9 3/9
Q4 2022 2023-02-06 C loweredmixedstable 7/9 3/9
Q3 2022 2022-10-31 B+ raisedmixedstable 7/9 2/9
Q2 2022 2022-08-01 B+ maintainedacceleratingstable 7/9 1/9
Q1 2022 2022-05-02 B+ raisedacceleratingstable 7/9 2/9
Q4 2021 2022-02-07 C+ maintainedacceleratingcontracting 7/9 3/9
Q3 2021 2021-11-01 B+ maintainedacceleratingstable 7/9 2/9
Q2 2021 2021-08-02 C+ maintainedacceleratingstable 7/9 4/9
Q1 2021 2021-05-03 B+ maintainedacceleratingstable 7/9 2/9
Q4 2020 2021-02-01 B+ maintainedacceleratingexpanding 7/9 2/9
Q3 2020 2020-11-02 C+ loweredmixedstable 8/9 2/9
Q2 2020 2020-08-03 B maintainedstablestable 7/9 2/9
Q1 2020 2020-05-04 C+ loweredacceleratingexpanding 7/9 2/9
Q4 2019 2020-01-27 A raisedacceleratingstable 7/9 2/9
Q3 2019 2019-11-04 C+ maintainedacceleratingstable 6/9 4/9
Q2 2019 2019-07-29 B maintainedmixedstable 7/9 2/9
Q1 2019 2019-04-22 C+ maintainedmixedstable 7/9 3/9
Q4 2018 2019-01-28 B maintainedmixedexpanding 7/9 2/9
Q3 2018 2018-10-29 C+ maintainedstableexpanding 7/9 3/9
Q2 2018 2018-07-30 D maintainedstablestable 6/9 2/9
Q1 2018 2018-05-07 B maintainedstablecontracting 7/9 2/9
Q4 2017 2018-01-29 B+ maintainedstablestable 8/9 1/9
Q3 2017 2017-10-23 B+ maintainedstablestable 6/9 2/9
Q2 2017 2017-07-24 B raisedstableexpanding 7/9 4/9
Q1 2017 2017-04-24 B maintainedstableexpanding 7/9 3/9
Q4 2016 2017-01-30 C+ maintainedstablecontracting 7/9 3/9
Q3 2016 2016-10-24 C+ raisedacceleratingstable 6/9 5/9
Q2 2016 2016-07-18 D loweredstablestable 5/9 4/9
Q1 2016 2016-04-18 D maintainedmixedcontracting 6/9 5/9
Q4 2015 2016-01-25 C raisedmixedcontracting 7/9 3/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of RMBS's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

B Q1 2017 earnings call 2017-04-24

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAXN · Axon Enterprise'sACIC · American Coastal InsuranACSAF · ACS, Actividades de ConsACU · Acme United CorporationADC · Agree Realty CorporationADPT · Adaptive Biotechnologies

RMBL   All “R” companies    RMCF

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.